Controlling Health Care Costs Paying for Prescription Drugs Around the World: Why Is the U.S. an Outlier? Issue Briefs / Oct 05, 2017
Controlling Health Care Costs The Case for Drug-Pricing Reform — The Cost of Inaction blog / May 26, 2021
Controlling Health Care Costs External Reference Pricing: The Drug-Pricing Reform America Needs? Issue Briefs / May 27, 2021
Controlling Health Care Costs How Federal Drug-Pricing Proposals Could Affect Medicaid blog / Aug 19, 2021
Controlling Health Care Costs Reducing Medicaid Prescription Drug Costs While Maintaining Beneficiary Access: MACPAC Recommendations for Accelerated-Approval Drugs blog / Aug 18, 2021
Controlling Health Care Costs The Impact of Pharmaceutical Wholesalers on U.S. Drug Spending Issue Briefs / Jul 20, 2022
Controlling Health Care Costs The Accelerated Approval Pathway for New Drug Therapies: Controversies and Proposed Fixes Explainer / Jul 14, 2022
Advancing Health Equity Disparities in the Use of New Diabetes Medications: Widening Treatment Inequality by Race and Insurance Coverage Issue Briefs / Jun 14, 2022
Controlling Health Care Costs Public Good vs. Private Gain: The Role of Public–Private Partnerships in Drug Innovation and Pricing Blog / Jun 08, 2022
Controlling Health Care Costs A Value-Based Approach to America’s Costly Prescription Drug Problem Blog / May 06, 2022
Controlling Health Care Costs Are Pharmacy Benefit Managers the Next Target for Prescription Drug Reform? Blog / Apr 20, 2022
Controlling Health Care Costs Oregon Seeks to Limit Medicaid Coverage of Accelerated-Approval Drugs Blog / Apr 05, 2022
Controlling Health Care Costs Generic Drugs Help Hold Down Costs, But Slowdowns in Development and Review Present Challenges Blog / Mar 24, 2022
Controlling Health Care Costs It’s the Patents, Stupid — Why Drugs Cost So Much in the U.S. Podcast / Feb 25, 2022